Jen Gong-Gershowitz
- Democratic
- Representative
- District 17
Creates the Drug Take-Back Act. Requires covered manufacturers to, no later than July 1, 2022 or 6 months after becoming a covered manufacturer, whichever is later, participate in an approved drug take-back program or have established and implemented a drug take-back program independently or as part of a group of covered manufacturers. Provides requirements for the drug take-back program and for manufacturer program operators. Requires each manufacturer program operator to submit a proposal for the establishment and implementation of a drug take-back program to the Environmental Protection Agency for review and approval. Contains provisions regarding changes or modifications to drug take-back programs, promotion of drug take-back programs, annual reports, funding, and reimbursement. Requires covered manufacturers and manufacturer program operators to submit an annual $5,000 registration fee. Specifies civil penalties for violation of the Act. Preempts home rule powers. Contains other provisions. Amends the Freedom of Information Act. Provides that proprietary information submitted to the Environmental Protection Agency under the Drug Take-Back Act is exempt from inspection and copying under the Act. Effective immediately. House Committee Amendment No. 1 Adds reference to: 415 ILCS 5/22.15 from Ch. 111 1/2, par. 1022.15 415 ILCS 5/22.55 Replaces everything after the enacting clause with the provisions of the introduced bill with the following changes. Provides that each covered manufacturer must, beginning January 1, 2024 (rather than no later than July 1, 2022) or 6 months after becoming a covered manufacturer, individually or collectively implement (rather than participate in) an approved drug take-back program. Requires a drug take-back program to provide for the collection, transportation, and disposal of covered drugs. Provides that specified requirements shall be undertaken by a drug take-back program or a covered manufacturer (rather than a manufacturer program operator). Requires the Environmental Protection Agency to review all proposals in conjunction with one another to ensure the proposals are coordinated to achieve authorized collection site coverage. Requires the Agency to either approve, reject, or approve with modification a proposal within 90 days after receiving it. Requires drug take-back program promotion to be implemented by all drug take-back programs collectively. Provides that a manufacturer program operator shall (rather than may) allocate administration and operation costs of programs to participating covered manufacturers. Requires each covered manufacturer and manufacturer program operator to register with the Agency and submit the registration fee by January 1, 2023 (rather than April 1, 2022), and by January 1 (rather than April 1) of each year thereafter. Removes language requiring penalties collected under the Act to be used in accordance with the Act's provisions. Removes language allowing the Agency to impose a civil penalty for a violation of the Act of $7,000 per violation per day. Makes other changes. Amends the Environmental Protection Act. Provides that moneys in the Solid Waste Management Fund shall be used for the administration of the Drug Take-Back Act. Removes provisions requiring the Agency to (1) develop and implement a public information program regarding household waste drop-off points that accept pharmaceutical products, as well as mail-back programs; (2) develop a sign that provides information on the proper disposal of unused pharmaceutical products; and (3) establish, by rule, a statewide medication take-back program by June 1, 2016 to ensure that there are pharmaceutical product disposal options regularly available for residents across the State. Makes other changes. Effective immediately. House Floor Amendment No. 2 Provides that "covered drug" means, among other things, a drug. Makes a typographical change. Senate Committee Amendment No. 1 In provisions of the Drug Take-Back Act, makes the following changes. Provides that "covered drug" does not include drugs sold at retail as a unit dose package or homeopathic drugs. Makes changes to the definition of "proprietary information". Provides that program promotion requirements do not apply to any drug take-back program established prior to the Act's effective date that provides promotional or educational materials to the public about the proper collection and management of covered drugs. Provides that each covered manufacturer and covered manufacturer program operator shall submit a registration fee of $2,500 (rather than $5,000). Senate Committee Amendment No. 2 Removes language providing that the definition of "covered manufacturer" does not include a pharmacy. Provides that private label distributors and repackagers are not covered manufacturers. Senate Floor Amendment No. 3 Requires the Environmental Protection Agency to provide a 30-day public comment period on drug take-back program proposals and revised proposals during specified 90-day periods. Provides that the reason for the Agency's rejection of a drug take-back program proposal must be provided in the written notification to the manufacturer program operator.
Governor Approved
Public Act . . . . . . . . . 102-1055
Effective Date June 10, 2022
Sent to the Governor
Added as Alternate Co-Sponsor Sen. Jacqueline Y. Collins
Motion to Reconsider Vote - Withdrawn Rep. Daniel Didech
Passed Both Houses
Senate Committee Amendment No. 2 House Concurs 095-014-000
Motion Filed to Reconsider Vote Rep. Daniel Didech
House Concurs
Senate Floor Amendment No. 3 House Concurs 095-014-000
Senate Committee Amendment No. 1 House Concurs 095-014-000
Senate Committee Amendment No. 2 Motion to Concur Recommends Be Adopted Rules Committee; 003-001-000
Senate Floor Amendment No. 3 Motion to Concur Recommends Be Adopted Rules Committee; 003-001-000
Senate Committee Amendment No. 1 Motion to Concur Recommends Be Adopted Rules Committee; 003-001-000
Senate Committee Amendment No. 2 Motion Filed Concur Rep. Jennifer Gong-Gershowitz
Senate Floor Amendment No. 3 Motion to Concur Referred to Rules Committee
Senate Committee Amendment No. 2 Motion to Concur Referred to Rules Committee
Senate Committee Amendment No. 1 Motion to Concur Referred to Rules Committee
Senate Floor Amendment No. 3 Motion Filed Concur Rep. Jennifer Gong-Gershowitz
Senate Committee Amendment No. 1 Motion Filed Concur Rep. Jennifer Gong-Gershowitz
Recalled to Second Reading
Placed on Calendar Order of Concurrence Senate Amendment(s) 1, 2, 3
Arrived in House
Third Reading - Passed; 046-002-000
Placed on Calendar Order of 3rd Reading
Senate Floor Amendment No. 3 Adopted; Fine
Added as Alternate Co-Sponsor Sen. Laura Ellman
Added as Alternate Chief Co-Sponsor Sen. Patricia Van Pelt
Added as Alternate Chief Co-Sponsor Sen. Sara Feigenholtz
Added as Alternate Co-Sponsor Sen. Ann Gillespie
Senate Floor Amendment No. 3 Recommend Do Adopt Executive; 015-000-000
Senate Floor Amendment No. 3 Assignments Refers to Executive
Senate Floor Amendment No. 3 Referred to Assignments
Senate Floor Amendment No. 3 Filed with Secretary by Sen. Laura Fine
Do Pass as Amended Executive; 016-000-000
Senate Committee Amendment No. 1 Adopted
Senate Committee Amendment No. 2 Adopted
Placed on Calendar Order of 3rd Reading March 24, 2022
Second Reading
Placed on Calendar Order of 2nd Reading
Senate Committee Amendment No. 1 Assignments Refers to Executive
Senate Committee Amendment No. 2 Assignments Refers to Executive
Senate Committee Amendment No. 2 Filed with Secretary by Sen. Laura Fine
Senate Committee Amendment No. 2 Referred to Assignments
Senate Committee Amendment No. 1 Referred to Assignments
Senate Committee Amendment No. 1 Filed with Secretary by Sen. Laura Fine
Assigned to Executive
Referred to Assignments
First Reading
Added as Alternate Chief Co-Sponsor Sen. Antonio Muñoz
Chief Senate Sponsor Sen. Laura Fine
Placed on Calendar Order of First Reading
Third Reading - Short Debate - Passed 096-013-000
Arrive in Senate
Second Reading - Short Debate
Placed on Calendar Order of 3rd Reading - Short Debate
House Floor Amendment No. 2 Adopted
House Floor Amendment No. 2 Recommends Be Adopted Rules Committee; 004-000-000
House Floor Amendment No. 2 Referred to Rules Committee
House Floor Amendment No. 2 Filed with Clerk by Rep. Jennifer Gong-Gershowitz
Added Co-Sponsor Rep. Jaime M. Andrade, Jr.
Placed on Calendar 2nd Reading - Short Debate
Added Co-Sponsor Rep. Mark Luft
Added Co-Sponsor Rep. Joyce Mason
Do Pass as Amended / Short Debate Prescription Drug Affordability & Accessibility Committee; 015-002-000
Added Co-Sponsor Rep. Martin McLaughlin
House Committee Amendment No. 1 Adopted in Prescription Drug Affordability & Accessibility Committee; by Voice Vote
House Committee Amendment No. 1 Rules Refers to Prescription Drug Affordability & Accessibility Committee
Added Co-Sponsor Rep. Lawrence Walsh, Jr.
Added Co-Sponsor Rep. Anthony DeLuca
Added Co-Sponsor Rep. Ann M. Williams
Added Co-Sponsor Rep. Robyn Gabel
Added Co-Sponsor Rep. Ryan Spain
House Committee Amendment No. 1 Filed with Clerk by Rep. Jennifer Gong-Gershowitz
House Committee Amendment No. 1 Referred to Rules Committee
Added Co-Sponsor Rep. Robert Rita
Added Chief Co-Sponsor Rep. Tom Demmer
Assigned to Prescription Drug Affordability & Accessibility Committee
Rule 19(a) / Re-referred to Rules Committee
Added Chief Co-Sponsor Rep. Dagmara Avelar
Added Co-Sponsor Rep. Michelle Mussman
Added Co-Sponsor Rep. Kambium Buckner
Added Co-Sponsor Rep. Deb Conroy
Assigned to Prescription Drug Affordability & Accessibility Committee
Added Co-Sponsor Rep. Kelly M. Cassidy
Added Co-Sponsor Rep. Anne Stava-Murray
Added Co-Sponsor Rep. Terra Costa Howard
First Reading
Referred to Rules Committee
Filed with the Clerk by Rep. Jennifer Gong-Gershowitz
Bill Text Versions | Format |
---|---|
Introduced | HTML PDF |
Engrossed | HTML PDF |
Enrolled | HTML PDF |
House Amendment 001 | HTML PDF |
House Amendment 002 | HTML PDF |
Senate Amendment 001 | HTML PDF |
Senate Amendment 002 | HTML PDF |
Senate Amendment 003 | HTML PDF |
Document | Format |
---|---|
Public Act |
Data on Open States is updated periodically throughout the day from the official website of the Illinois General Assembly.
If you notice any inconsistencies with these official sources, feel free to file an issue.